-+ 0.00%
-+ 0.00%
-+ 0.00%

VERTEX PHARMACEUTICALS INCORPORATED : LEERINK PARTNERS RESUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $594

Reuters·09/21/2026 10:03:47

Please log in to view news